Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $24.40.

A number of research analysts recently issued reports on the company. RODMAN&RENSHAW lowered Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Wedbush lowered Alto Neuroscience from an "outperform" rating to a "neutral" rating and reduced their price objective for the company from $29.00 to $4.00 in a research report on Wednesday. Robert W. Baird reduced their price objective on Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a research report on Wednesday. Rodman & Renshaw lowered Alto Neuroscience from a "buy" rating to a "neutral" rating in a research report on Wednesday. Finally, William Blair restated an "outperform" rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. raised its stake in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $128,000 after acquiring an additional 3,000 shares in the last quarter. Bowie Capital Management LLC bought a new stake in Alto Neuroscience during the 2nd quarter valued at $462,000. TD Asset Management Inc bought a new stake in shares of Alto Neuroscience in the 2nd quarter worth $928,000. Rhumbline Advisers bought a new stake in shares of Alto Neuroscience in the 2nd quarter worth $113,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Alto Neuroscience in the 2nd quarter worth $252,000.

Alto Neuroscience Stock Performance

Shares of ANRO traded down $0.23 during mid-day trading on Thursday, hitting $4.13. The stock had a trading volume of 2,779,196 shares, compared to its average volume of 349,201. The company's fifty day simple moving average is $12.22 and its two-hundred day simple moving average is $12.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85. Alto Neuroscience has a fifty-two week low of $4.04 and a fifty-two week high of $24.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.07. As a group, sell-side analysts predict that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.